Accession Number: | 0001562180-20-001619 |
Date: | 2020-02-20 |
Issuer: | DERMIRA, INC. (DERM) |
Original Submission Date: |
GILBERT HALLEY E
C/O DERMIRA, INC.
275 MIDDLEFIELD ROAD, SUITE 150
MENLO PARK, CA 94025
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
DIRECTOR STOCK OPTIONS (RIGHT TO BUY) | 8.05 | 2020-02-20 | deemed execution date | D | 20,000 (d) | 2029-11-10 | common stock 20,000 | $8.05 | 0 | direct |
ID | footnote |
---|---|
f1 | pursuant to the agreement and plan of merger (the "merger agreement") dated january 10, 2020, by and among dermira, inc. ("dermira"), eli lilly and company, an indiana corporation ("lilly"), and bald eagle acquisition corporation, a delaware corporation and a wholly owned subsidiary of lilly ("merger sub"), merger sub merged with and into dermira, with dermira surviving as a wholly owned subsidiary of lilly (the "merger"), effective as of february 20, 2020. pursuant to the merger agreement, each issued and outstanding share (the "shares") of dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "offer price"), net to the seller in cash, without interest, and subject to withholding taxes. |